MedTrace Logo

Study of Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma

NCT03600441 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 139

Last updated 2025-04-10

No results posted yet for this study

Summary

This study in patients with relapsed/refractory follicular lymphoma who have undergone at least 3 lines of therapy. Patients will receive abexinostat 80 mg (4 × 20 mg tablets) twice a day (BID) in a "one week on, one week off" schedule.

Conditions

Interventions

DRUG

Abexinostat

Abexinostat tosylate salt is formulated into an oral tablet formulation and is available in 20 mg strength.

Sponsors & Collaborators

  • Xynomic Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Connie W Batlevi, MD,PhD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-08-27
Primary Completion
2027-12-31
Completion
2029-12-31
FDA Drug
Yes

Countries

  • United States
  • France
  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03600441 on ClinicalTrials.gov